LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND4 Y& P1 F0 l) H1 T
THERAPE UTIC PERSPECTIVES, u6 y2 z: D: [7 r" H
J. Mazieres, S. Peters- M0 E* y0 ?) m8 r9 ?
Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
# w! _& v6 S3 c0 b4 ?outcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted* X) Q) I) q/ m9 F! f& E
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2: _ S$ n' f) ]
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations+ N% A+ u: r& P7 J
and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;/ S& V' V, r& L
disease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for; S, o) o+ Z! m( T4 g5 v$ |
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
+ i" X8 v$ ]" s5 glapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
# a/ _2 x: n: v4 r/ }9 i8 h22.9 months for respectively early stage and stag e IV patients.4 E3 s- O Q% }( |
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
$ K' |3 a3 u$ ~) `/ q% l4 Z4 zreinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
- B+ D3 I. ]9 W# G& i) E' Y, t- FHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
0 c2 W8 w- b3 D, {. _9 ]0 Oclinicaltrials.- i& ]. Q& v+ D; ^
|